

SUPPLEMENTAL FIGURE S1: Evaluation of CX3CL1 bone marrow levels in myeloma patients with or without bone disease. BM CX3CL1 plasma levels in multiple myeloma patients (A) with (W) or without (W/O) osteolytic lesions ($P = 0.34$, not significant (NS)) or (B) the presence of high bone disease (HBD) compared to low bone disease (LBD) ($P = 0.78$, NS).

